Ratings agency Standard & Poor's affirmed India's sovereign rating at "BBB-minus" with a "negative" outlook, reiterating there was a one-in-three chance of a ratings downgrade over the next 12 months, a statement said on Friday. Full Article
China president takes charge of sweeping economic reform plans - sources. Full Article
Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade. Full Coverage
Cipla gains on partner's contract win
Reuters Market Eye - Shares in drugmaker Cipla(CIPL.NS) rise 1.4 percent after Cipla Medpro (CMPJ.J) won a share in South Africa's $667 million contract, as it supplies the bulk of Cipla Medpro's drugs.
Dealers say the company may garner revenues of $30-40 million from Cipla Medpro's contract.
South Africa on Thursday awarded a $667 million contract to supply life-prolonging HIV medicine to 12 international and domestic firms, including Cipla Medpro, to deal with its biggest health problem.
Cipla also plans to offer $215 million for a majority stake in South Africa's Cipla Medpro to strengthen its presence in Africa's fast-growing market for cheap, generic versions of branded drugs.
- Tweet this
- Share this
- Digg this